Implementing assays for Direct Oral Anticoagulants
Research type
Research Study
Full title
A Critical Evaluation of assays for theraputic use of novel anticoagulants, alternatively known as Direct Oral Anticoagulants for use at Tameside General Hospital
IRAS ID
212031
Contact name
Haleema Yaseen
Contact email
Sponsor organisation
Tameside General Hospital
Clinicaltrials.gov Identifier
N/A, N/A
Duration of Study in the UK
0 years, 2 months, 14 days
Research summary
The purpose of this study is to implement and validate assays for the new anticoagulants that have recently been introduced to the market. Dabigatran, Apixaban and Rivaroxiban. These drugs do not require monitoring like Warfarin and therefore pose as an advanatge. However, there are side effects to this. If a patient was to overdose or undergo an emergency procedure, the clinicians would not be able to differenciate whether the bleeding is due to the anticoagulant OR the procedure itself. This is harmful for the patient because it poses as a life threatening risk. The purpose of my study is develop tests that can distinguish normal results and abnormal results that can aid doctors in providing the best treatment to stop the bleeding as there is no definitive antidote readily available as of yet.
REC name
North East - Tyne & Wear South Research Ethics Committee
REC reference
16/NE/0350
Date of REC Opinion
19 Oct 2016
REC opinion
Favourable Opinion